Poxel

Poxel Sa

Sébastien Bolze

Sophie Hallakou-Bozec

Daniel Cravo

Pascale Fouqueray

Vincent Jacques

Christine G Charon

Franck F Lepifre

Jean-Denis Durand

Paul Strumph

Margaret Smith Fletcher

Karen Segal

Brandon Dale Swift

Steve Piscitelli

Ruby Holder

Laurent Faveriel

Sophie Bozec

Laure Françoise Valérie Navarre

Sophie Hallakou-bozec

Christophe Arbet-Engels

Julie Dubourg

Bill Symonds

Sheila DeWitt

Marc Lanz

Laure Navarre

Maxime Laugier

Anthony O'sullivan

Deniz Arican

Emeline Gardette

Sheila Dewitt

Franck Lepifre

The invention relates to a process for preparing a monohydrate potassium salt of a 5 thienopyridone derivative. It also relates to a monohydrate potassium salt of a thienopyridone derivative and its use in medicine, in particular for treating or preventing metabolic disorders, such as NASH.

Monohydrate potassium salt of a thienopyridone derivative and its preparation process

The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD)

The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.

Methods of treating subjects having diabetes with chronic kidney disease

The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of genetic neurodegenerative diseases selected from adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN).

Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy

This invention pertains to a film-coated tablet comprising an inner core and an external coating, wherein the inner core comprises a high proportion of a specific triazine derivative, namely 2-amino-3,6-dihydro-4-dimethylamino-6-methyl-1,3,5-triazine and pharmaceutically acceptable salts thereof, and a specific binder. It is also directed to the use of these tablets in the treatment of diabetes and/or complications thereof. This invention is further directed to a specific process for the manufacture of these film-coated tablets, which involves a granulation step in a high-shear mixer.

Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

The invention provides methods of synthesis of enantiopure deuterium enriched R-pioglitazone with structure of compound (IV), or a pharmaceutically acceptable salt thereof: The invention further provides chemical intermediates useful in the synthesis of compound (IV), and methods of synthesizing those intermediates.

Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.

Crystalline forms of deuterium-enriched pioglitazone

The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, inflammation, cancer and cardiovascular diseases. 

Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof

Activators of AMPK and therapeutic uses thereof The invention relates to compounds that are direct activators of AMPK (AMP-activated protein kinase) and their use in the treatment of disorders regulated by activation of AMPK. For instance, compounds according to the invention are useful for the treatment of diabetes, metabolic syndrome, obesity, liver disease, hepatic steatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steato-hepatitis (NASH), liver fibrosis, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, inflammation, cancer, cardiovascular diseases, atherosclerosis, high blood pressure, retinopathies or neuropathies. 

Thienopyridone derivatives useful as activators of AMPK

The present invention relates to triazine derivatives of formula (I) for their use in the treatment of type 1 diabetes mellitus, and to compositions comprising said triazine derivatives. 

Treatment of type 1 diabetes

Growing community of inventors

Massieux, France

Sébastien Bolze